Silo Pharma (SILO) Change in Accured Expenses (2012 - 2026)
Silo Pharma (SILO) posted Change in Accured Expenses of $54662.0 for Q1 2026, up 193.99% sequentially from -$58156.0 in Q4 2025, and up 111.61% YoY from $25831.1 in Q1 2025.
Silo Pharma (SILO) Change in Accured Expenses (2012 - 2026) Analysis & Trends
Silo Pharma has reported Change in Accured Expenses for 12 years, with the latest figure at $54662.0 in Q1 2026.
- Quarterly Change in Accured Expenses rose 111.61% year-over-year to $54662.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$468059.0 (down 828.7% YoY) and the FY2025 annual result came in at -$993414.0, down 256.94% from the prior year.
- Change in Accured Expenses advanced to $54662.0 in Q1 2026 per SILO's latest filing, from -$58156.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $611165.0 in Q4 2024 and troughed at -$470693.0 in Q1 2025.
- A 5-year average of -$1187.9 and a median of $54662.0 in 2026 frame the typical range for Change in Accured Expenses.
- The widest YoY moves for Change in Accured Expenses: up 331361.54% in 2023, down 751.82% in 2023.
- Over 5 years, Change in Accured Expenses stood at $140571.0 in 2022, then slumped by 31.12% to $96819.0 in 2023, then soared by 531.24% to $611165.0 in 2024, then sank by 109.52% to -$58156.0 in 2025, then surged by 193.99% to $54662.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $54662.0, -$58156.0, and -$341558.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Silo Pharma | 2.92 Mn | 2.92 Mn | - | -178,917.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -178,917.00 |
| Jun 30, 2026 | -178,917.00 |
| Mar 31, 2026 | 54,662.00 |
| Mar 31, 2026 | 54,662.00 |
| Dec 31, 2025 | -58,156.00 |
| Dec 31, 2025 | -58,156.00 |
| Sep 30, 2025 | -341,558.00 |
| Sep 30, 2025 | -341,558.00 |
| Jun 30, 2025 | -123,007.00 |
| Jun 30, 2025 | -123,007.00 |
| Mar 31, 2025 | -470,693.00 |
| Mar 31, 2025 | -470,693.00 |
| Dec 31, 2024 | 611,165.00 |
| Dec 31, 2024 | 611,165.00 |
| Sep 30, 2024 | -278,047.00 |
| Sep 30, 2024 | -278,047.00 |
| Jun 30, 2024 | 201,807.00 |
| Jun 30, 2024 | 201,807.00 |
| Mar 31, 2024 | 98,082.00 |
| Mar 31, 2024 | 98,082.00 |